By Ian Lloyd 22 Mar 2017
Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.
Follow company pipelines in over 40 countries and probe more than 30 years of R&D history to uncover trends that have, and will, impact the drug development industry.
How it works
Pharmaprojects provides comprehensive coverage of drug development, from discovery to end of patent and market exclusivity. Its intuitive search interface supports quick access to disease-, company-, or country-specific drug development results. These can be visualized quickly via an analytic dashboard, or exportable into several formats.
How it can help
Pharmaprojects' expert analysts track in- and out-licensing acitivity making it easy to identify opportunities or market saturation.These analysts will conduct primary research on your behalf to try to uncover additional information around your drug or company of interest. And, the deep linking to Trialtrove means that you will be on top of any clinical trial developments for your disease, company, or therapeutic mechanism of interest.
Analyst reviewed and enriched trial profiles, including tags for key attributes
Development history, licensing information, molecular structure and more
Attain an analysis of drug development trends from 1995 to date
Unlimited research support from experienced industry analysts
Instantly generate tables and charts of key trial counts
By Andrew Frost 22 Mar 2017
With the recent controversy surrounding the approval and launch of the first wave of PCSK9 inhibitors (focussing mainly on the extremely high cost in comparison to statin therapies), it may be easy to forget that the dyslipidaemia space has also been plagued by a number of high profile and costly failures too.
Topic Clinical trials
Pharmaprojects, Biomedtracker, Trialtrove
By Rachel Meighan-Mantha 22 Mar 2017
Epigenetic Drugs in Oncology: Current Clinical Landscape and Emerging Trends
27 Feb 2017
Over 350 million people worldwide are suffering from rare diseases. Which is why it is necessary to understand the rare disease landscape to date.
By Roger Longman 25 Nov 2016
Citeline Doro's analyzes the increased activity of clinical trials located in East Asia. This report gives a detailed look into characteristics of trials currently being conducted and planned in East Asia.
Topic Infectious diseases
By Doro Shin 25 Jan 2016
On April 27, 2016, Informa will host its inaugural Clinical and Research Excellence (CARE) Awards to honor those in clinical R&D who are making a difference and committed to making human lives better.
By Benjamin Graham 01 Dec 2015
For World AIDS Day, we look at current and upcoming novel single tablet regimens (STRs) for HIV treatment. STR’s primary advantage is that they simplify treatment and this leads to greater patient adherence, lower resistance emergence and overall improved outcomes over more traditional cocktails of antiretroviral drugs
By Jonathan Stephens 24 Nov 2015
When considering cancer in men, prostate cancer could be described as ‘all too frequent’. Indeed, the annual month of ‘Movember’ is here once again and serves as a stark reminder that men worldwide are still dying too young from this disease.Worldwide prostate cancer is currently the second most common cancer in males and the fourth most common cancer overall, with over 1.1 million new cases diagnosed in 2012
By Natasha Boliter 28 Oct 2015
With the recent launch of Regeneron/Sanofi’s Praluent® and Amgen’s Repatha®, which are both fully human anti-PCSK9 monoclonal antibodies, it is interesting to consider the other molecular approaches being pursued in the burgeoning PCSK9 inhibitor arena.
By Jonathan Stephens 06 Jul 2015
Since its inception in the mid-20th century, chemotherapy has been the mainstay of cancer treatment and has become increasingly specific and effective.
By Benjamin Graham 25 Mar 2015
Continuing from part 1 of this series (https://citeline.com/part-1-current-status-ebola-vaccine-development/), which addressed the clinical development of a vaccine for Ebola virus disease (EVD), part 2 will be assessing the status of treatments for EVD.
By Gabrielle Gessner 20 Mar 2015
While there was a decline in new cases of Ebola in December and January in the three West African countries most affected by the virus (Liberia, Guinea and Sierra Leone), this trend seems to have ended. Ebola transmission was widespread in Guinea and Sierra Leone in February, but remained low in Liberia, according to the World Health Organization (WHO Ebola Situation Report, 25 Feb 2015, http://apps.who.int/ebola/en/ebola-situation-report/situation-reports/ebola-situation-report-25-february-2015 ). Unfortunately, a significant portion of new cases do not have a known cause of transmission. The race for a vaccine has also heated up, with 6 vaccines now in clinical development, both single vaccines and multiple vaccine regimens.
By Laurie Withington 18 Sep 2014
Just last month, the US FDA accepted Sandoz’s filing for biosimilar filgrastim, Zarzio. Sandoz is the first company to announce it has filed for approval under the biosimilars pathway created in the Biologics Price Competition and Innovation Act of 2009 (BPCIA). In the EU, Inflectra/Remsima™ (infliximab) became the world’s first biosimilar monoclonal antibody to be granted approval from an advanced and developed nations’ regulatory body. It has already had a limited launch in certain EU markets and a full roll-out is expected in early 2015. Companies developing biosimilars intended for regulated markets are presumably optimistic about these events which are helping to pave the way for future biosimilar development in advanced nations.
By Jonathan Stephens 02 Dec 2013
Whither the pharmaceutical blockbuster? The pharma industry entered the 21st century buoyed by a series of mega hits that had carried it through the nineties on a wave of promise.
Ian specializes in
+30 year(s) experience
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: